Business Summary: Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Sanofi SA (ADR) revenues increased 6% to EUR11.24B. Net income before extraordinary items decreased 6% to EUR1.59B. Revenues reflect Other segment increase of 55% to EUR146M, United States segment increase of 14% to EUR5.29B, Europe segment increase of 6% to EUR2.16B. Basic Earnings per Share excluding Extraordinary Items decreased from EUR1.38 to EUR1.32.